CSPC PHARMA (01093.HK): NDA for Envi Trastuzumab Injection Accepted by NMPA
NewTimeSpace News: CSPC Pharma (01093.HK) released a voluntary announcement on 17 July 2026. The New Drug Application for Envi Trastuzumab Injection developed by the Group has been accepted by the National Medical Products Administration (NMPA). Classified as a Class 1 therapeutic biological product, the candidate is indicated for adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2 therapies.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC PHARMA (01093.HK): Phase II Clinical Trial of SYH2069 Injection for Weight Management in Overweight or Obese Adults Launched at First Study Site in China
- CSPC PHARMA (01093.HK): High-potency amylin receptor agonist SYH2092 injection approved for clinical trials in China
- CSPC PHARMA (01093.HK): SYS6090 granted FDA Fast Track designation for MSS/pMMR metastatic colorectal cancer
- CSPC PHARMA (01093.HK): SYS6010 meets primary endpoint in Phase III study for EGFR-mutant NSCLC after EGFR TKI failure
- CSPC PHARMA (01093.HK): Recombinant respiratory syncytial virus vaccine SYS6057 approved for clinical trials in the US
